Unknown

Dataset Information

0

Engineering the Direct Repeat Sequence of crRNA for Optimization of FnCpf1-Mediated Genome Editing in Human Cells.


ABSTRACT: FnCpf1-mediated genome-editing technologies have enabled a broad range of research and medical applications. Recently, we reported that FnCpf1 possesses activity in human cells and recognizes a more compatible PAM (protospacer adjacent motif, 5'-KYTV-3'), compared with the other two commonly used Cpf1 enzymes (AsCpf1 and LbCpf1), which requires a 5'-TTTN-3' PAM. However, due to the efficiency and fidelity, FnCpf1-based clinical and basic applications remain a challenge. The direct repeat (DR) sequence is one of the key elements for FnCpf1-mediated genome editing. In principle, its engineering should influence the corresponding genome-editing activity and fidelity. Here we showed that the DR mutants [G(-9)A and U(-7)A] could modulate FnCpf1 performance in human cells, enabling enhancement of both genome-editing efficiency and fidelity. These newly identified features will facilitate the design and optimization of CRISPR-Cpf1-based genome-editing strategies.

SUBMITTER: Lin L 

PROVIDER: S-EPMC6224799 | biostudies-other | 2018 Nov

REPOSITORIES: biostudies-other

altmetric image

Publications

Engineering the Direct Repeat Sequence of crRNA for Optimization of FnCpf1-Mediated Genome Editing in Human Cells.

Lin Li L   He Xiubin X   Zhao Tianyuan T   Gu Lingkai L   Liu Yeqing Y   Liu Xiaoyu X   Liu Hongyan H   Yang Fayu F   Tu Mengjun M   Tang Lianchao L   Ge Xianglian X   Liu Changbao C   Zhao Junzhao J   Song Zongming Z   Qu Jia J   Gu Feng F  

Molecular therapy : the journal of the American Society of Gene Therapy 20180901 11


FnCpf1-mediated genome-editing technologies have enabled a broad range of research and medical applications. Recently, we reported that FnCpf1 possesses activity in human cells and recognizes a more compatible PAM (protospacer adjacent motif, 5'-KYTV-3'), compared with the other two commonly used Cpf1 enzymes (AsCpf1 and LbCpf1), which requires a 5'-TTTN-3' PAM. However, due to the efficiency and fidelity, FnCpf1-based clinical and basic applications remain a challenge. The direct repeat (DR) se  ...[more]

Similar Datasets

| S-EPMC4927198 | biostudies-literature
| S-EPMC3799423 | biostudies-literature
| S-EPMC6342934 | biostudies-literature
| S-EPMC9579715 | biostudies-literature
| S-EPMC5709416 | biostudies-literature
| S-EPMC7335164 | biostudies-literature
| S-EPMC3160389 | biostudies-literature
| S-EPMC6862751 | biostudies-literature
| S-EPMC3557905 | biostudies-other
| S-EPMC5357160 | biostudies-literature